Arizona is taking a trip to the forefront of psychedelic research as Scottsdale Research Institute (SRI) gears up to lead a groundbreaking study on psilocybin mushrooms, also known as "magic mushrooms." According to a report from ABC15, SRI will measure the therapeutic effects of these mushrooms in treating life-threatening illnesses, marking the first time a DEA-approved clinical trial is using natural, self-grown psilocybin.
Combatting afflictions from chronic pain to post-traumatic stress disorder, this study carries promising potential for those grappling with severe health issues. In a testament to community effort, military veterans, firefighters, and individuals battling terminal diseases propelled the grant's approval by the Arizona legislature, securing $2.75 million of a $5 million kitty dedicated to psilocybin research. “Arizona is at the forefront of this clinical research, leading the charge in exploring innovative treatments for mental health and chronic pain,” Nicole Nichols, SRI Foundation President, elucidated in a statement relayed by the Business Journal.
The study's structure is a comparative one, with a two-part treatment plan which has a group digesting the mushrooms and another group taking a placebo. SRI, operating out of Scottsdale, plans to cultivate their own mushrooms and scrutinize the effects on the emotional states of patients with various illnesses. Sue Sisley, MD, President of SRI, highlighted the uniqueness of the research, telling the Business Journal, “Whole psilocybin mushrooms, with all of the molecules working together, could offer superior healing potential than one synthetic molecule.”
While the study's initial participant count is pegged at 24 patients, there's potential for expansion. Spanning a timeframe of four to six months per patient, researchers are hopeful the findings will underpin psilocybin's medical benefits - and, perhaps, be a stepping stone to legal medical use in the U.S. The pursuit is not just limited to psilocybin; SRI is also examining other psychoactive plants, like cannabis, to gauge medical efficacy. Illnesses in the spotlight for this research include, among other conditions, post-traumatic stress disorder, symptoms associated with long Covid, and obsessive-compulsive disorder.
